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Abstract The current standard interferon-alpha (IFN-α)-
based therapy for chronic hepatitis C virus (HCV) infection
is only effective in approximately half of the patients,
prompting the need for alternative treatments. RNA
interference (RNAi) represents novel approach to combat
HCV by sequence-specific targeting of viral or host factors
involved in infection. Monotherapy of RNAi, however, may
leadtotherapeuticresistancebymutationalescapeofthevirus.
Here, we proposed that combining lentiviral vector-mediated
RNAi and IFN-α could be more effective and avoid
therapeutic resistance. In this study, we found that IFN-α
treatment did not interfere with RNAi-mediated gene silenc-
ing. RNAi and IFN-α act independently on HCV replication
showingcombinedantiviralactivitywhenusedsimultaneously
orsequentially.Transductionofmousehepatocytesinvivoand
i nv i t r ow a sn o te f f e c t e db yI F N - α treatment. In conclusion,
RNAi and IFN-α can be effectively combined without cross-
interference and may represent a promising combinational
strategy for the treatment of hepatitis C.
Keywords RNAi.IFN-α.Genetherapy.Lentiviral vector.
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Abbreviations
HCV Hepatitis C virus
IFN-α Interferon-alpha
RNAi RNA interference
siRNA Small interfering RNA
shRNA Small hairpin RNA
LV Lentiviral vector
GFP Green fluorescent protein
Introduction
The hepatitis C virus (HCV) infection remains a major
cause of chronic liver disease with an estimated 170 million
carriers worldwide. The current standard therapy, pegylated
interferon-alpha (IFN-α) in combination with ribavirin, has
achieved substantial success [1, 2]. However, still half of
the patients fail to develop a sustained virologic response
after this therapy. To improve treatment outcomes, novel
monotherapies or alternative combination of IFN-α based
therapies are urgently required.
RNA interference (RNAi), the degradation of cognate
mRNA by small interfering RNA (siRNA), has emerged as a
novel therapeutic entity for viral infections. Since the HCV
genome is a single-stranded RNA that functions as both a
template for transcription and template for a negative strand
replication intermediate, it is a prime candidate for RNAi [3].
Instead of a 5′ cap, the internal ribosome entry site (IRES),
located at the 5′ noncoding region of the viral genome, plays
an essential in initiating translation [4]. Because of the most
conserved sequence within the viral genome, IRES seems an
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demonstrated inhibition of HCV replication by targeting this
region [5–7]. HCV replication is mediated by NS5B, an
RNA-dependent RNA-polymerase that lacks proofreading
abilities. As a result of extremely high mutation rate (10
3 per
nucleotide per generation) and replication rate (10
12 virions
per day) in patients, HCV quasispecies are generated [8].
NS5b region has been shown to be very effective for RNAi-
induced suppression of HCV replication [9]. Host cellular
factors involved in the viral entry, such as CD81, Claudin-1,
Occludin, or SR-B1, could also be candidate targets for
RNAi antiviral therapy [10–12]. Knockdown of CD81 by
RNAi significantly prevented the binding of Huh7 cells to
E2 protein [13]. A definitive proof of the therapeutic value of
CD81 in vivo was provided by a recent study showing that
treatment with anti-CD81 antibodies completely protected
human liver-uPA-SCID mice from a subsequent challenge
with HCV consensus strains of different genotypes [14].
The success of RNAi in therapeutic application also
depends on an efficient delivery system, which can support
long-term siRNA production and continuous gene silencing.
Integrating self-inactivating lentiviral vector (LV) can achieve
these criteria by encoding small hairpin RNA (shRNA), a
precursor of siRNA that is cleaved into biologically active
siRNA by host cell enzyme, Dicer [15, 16].
Similar to existing antiviral monotherapies, a new mono-
therapybasedonasingleRNAitargetwilllikelyfailduetothe
development of resistance. HCV can potentially overcome the
antiviral effects of RNAi through several mechanisms,
including genomic diversity, mutational escape, and attenua-
t i o no fR N A im a c h i n e r y[ 17–20]. RNA viruses like HIV and
HCV are highly adaptive in this context, and mutational
escape from therapy has been documented against single
RNAi treatments [18, 21]. Thus, a combined strategy would
be necessary for eliminating HCV infection. Previous studies
reported by our group and others have shown that simulta-
neously targeting both viral and host cell elements by RNAi
could increase the potency of antiviral therapies [13, 21–23].
IFN-α possesses indirect antiviral activity by stimulating
genes that can lead to a non-virus-specific antiviral response,
whereas RNAi can directly interfere with viral entry and
replication through targeting viral RNA genome or mRNA of
cellular factors. Based on their complementary antiviral
mechanisms, we propose that combining RNAi with IFN-α
may prevent therapeutic resistance and exhibit enhanced
antiviral activity. Moreover, the additional combination of
ribavirin to RNAi and IFN-α may further improve the
therapeutic effects in the treatment of chronic hepatitis C.
To date, very little is known about the interaction of
exogenous IFN-α with lentiviral vector delivery and the
antiviral action of RNAi. Reports have suggested that the
administration of lentiviral vectors to mice triggers a rapid
and transient type I IFN response (i.e., IFN-α and IFN-β).
In animals that lack the capacity to produce type I IFN,
dramatic increases in transduction to hepatocytes were seen,
indicating that endogenous IFNs may interfere [24].
Inthecurrentstudy,weinvestigatedtheeffectofcombining
lentiviral-mediated RNAi with IFN-α in an in vitro HCV
replicationmodel.The results indicatethatIFN treatmentdoes
not affect the transduction efficiency of hepatocytes in vitro
and in vivo. Moreover, IFN did not interfere with RNAi-
mediated knockdown of host cell target genes, including
CD81, and showed combined antiviral activity with shRNAs
directed against the HCV genome. The combined efficacy of
RNAi and IFN-α may provide new opportunities for highly
effective antiviral therapy for hepatitis C.
Materials and methods
Cell culture
Cell monolayers of the human embryonic kidney epithelial
cell line HEK293 and human hepatoma cell line Huh7 and
Huh6weremaintainedinDulbecco's modified Eagle medium
(DMEM; Invitrogen–Gibco, Breda, The Netherlands) and
complemented with 10% v/v fetal calf serum (Hyclone,
Logan, Utah), 100 IU/ml penicillin, 100 mg/ml strepto-
mycin, and 2 mML-glutamine (Invitrogen–Gibco;
cDMEM). Huh7 cells containing a subgenomic HCV bicis-
tronic replicon (I389/NS3-3V/LucUbiNeo-ET, Huh7-ET)
were maintained with 250 μg/ml G418 (Sigma, Zwijndrecht,
The Netherlands) [25].
Construction and production of lentiviral vectors
The vectors, LV expressing green fluorescent protein (LV-
GFP), LV-shCD81, LV-shIRES, and LV-shNS5b containing
shRNA cassettes were constructed and produced as
previously reported [13]. LV-shIRES targets HCV IRES
region (AGGUCUCGUAGACCGUGCA 321-340). LV-
shNS5b targets the viral NS5b region (GACACUGAGA
CACCAAUUGAC 6367-6388). LV-shCD81 targets human
CD81 mRNA (GGAUGUGAAGCAGUUCUAU 594-614).
Briefly, a third-generation lentiviral packaging system
pND-CAG/GFP/WPRE containing shRNA expression cas-
sette targeting HCV IRES, NS5b region, or viral receptor
CD81 was used to produce high-titer VSV-G-pseudotyped
lentiviral vectors in HEK293 cells. Vector supernatants
were removed 36 and 48 h post-transfection, passed
through a 0.45-μM filter, and concentrated 1,000-fold by
ultracentrifugation. Plasmid SHC005 containing both
shGFP cassette and puromycin selectable marker was
obtained from Erasmus Center for Biomics (Rotterdam,
The Netherlands). LV-shGFP was produced in the third-
generation lentiviral packaging system as mentioned above.
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Concentrated LV stocks were titrated using HEK293 cells 24 h
after infection, with transduction efficiency based on the
numberofGFP-positive cells asdetermined byflow cytometry
(FACSCalibur; BD BioSciences, Mountain View, CA, USA).
Transduction efficiency of LV-GFP in the presence of IFN-α
was tested using this method in Huh7 cells 3 days post-
infection. Transduction efficiency of LV-shIRES and LV-
shNS5b in Huh7-ET cells was also tested by this method.
Pegylated IFN-α 2a (dissolved in water) was provided by
Roche (Basel, Switzerland). CD81 expression was determined
using flow cytometry by staining with phycoerythrin conju-
gated mouse antihuman CD81 monoclonal antibody (BD
Pharmingen, San Diego, USA). Mouse IgG1 was used as
isotype-matched control antibody (BD Pharmingen).
In vivo LV transductions in mice
Eleven-week-old female NOD/LtSz-scid/scid (NOD/SCID)
mice were injected intravenously with suboptimal dose of LV-
GFP (5×10
6 transducing units in 0.25 ml PBS) in the tail
vein. Three mice were injected subcutaneously with pegylated
IFN-α 2b (Intron A, Schering-Plough, Kenilworth, NJ, USA)
a t6hb e f o r ea n d7 2ha f t e ri n t r a v enous administration of LV-
GFP. The dose of peg-IFN-α per injection was 30 μg/kg body
weight, as previously described [26] .T w om i c ew e r ei n j e c t e d
with vector alone and one animal served as negative control.
After 7 days, mice were killed and livers were harvested.
Mouse liver tissue was digested by collagenase type IV
(Sigma, Zwijndrecht, The Netherlands) for 30 min at 37°C in
order to generate a single-cell suspension. Transduction
efficiency was determined by the percentage of GFP-positive
hepatocytes using flow cytometric analysis (FACSCalibur,
BD BioSciences).
Luciferase assay
Luciferin potassium salt (100 mM; Sigma) was added to
Huh7-ET cells and incubate for 30 min at 37°C. Luciferase
activity was quantified using a LumiStar Optima lumines-
cence counter (BMG LabTech, Offenburg, Germany).
Statistical analysis
Statistical analysis was performed by usingeither matched pair
nonparametric test (Wilcoxon signed-rank test) or the non-
paired, nonparametric test (Mann–Whitney test; GraphPad
Prism software). P values less than 0.05 were considered as
statistically significant.
Results
Potent inhibition of HCV replication by lentiviral
vector-mediated RNAi
A subgenomic replicon cell line (Huh7-ET), containing
HCV nonstructural sequences and a luciferase reporter gene
[25, 27], was used to determine the antiviral potency of
IFN-α and RNAi (Fig. 1a). HCV replication was monitored
by measuring luciferase activity. Robust reduction of
luciferase activity (97±2% inhibition, mean±SD, n=9)
was observed from 2.5 to 100 IU/ml of IFN-α.
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Fig. 1 Inhibition of HCV replication by IFN-α or LV-shNS5B. a
Huh7-ET replicon was used for testing HCV replication by monitoring
luciferase activity. IFN-α treatment inhibits viral replication in a dose-
dependent manner. Profound reduction of luciferase activity (97±2%
inhibition, mean±SD, n=9) was observed from 2.5 to 100 IU/ml
concentration of IFN-α. b LV-shNS5b contains both GFP reporter
gene and shRNA targeting HCV were tested. Huh7-ET treated with
increasing dose of LV-shNS5b resulted in higher levels of transduction
efficiency and inhibition of HCV replication, monitored by GFP-
positive population and luciferase activity, respectively. Maximum
inhibition of HCV replication was observed at high dose (20 or 25
MOI) by 98±3% (mean±SD, n=6). *P<0.01 (Wilcoxon test)
significantly different from untreated conditions
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targeting HCV NS5b sequence was tested. Huh7-ET treated
with increasing dose of LV-shNS5b resulted in higher levels
of transduction efficiency and inhibition of HCV replication
as monitored by GFP reporter gene expression and
luciferase activity, respectively. Maximum inhibition of
HCV replication was observed at multiplicity of infection
(MOI) of 20 and 25 by 98±3% (mean±SD, n=6; Fig. 1b).
The results indicate that RNAi-mediated inhibition of HCV
replication can be as effective as IFN-α in Huh7-ET model.
Exogenous IFN-α has no negative impact on lentiviral
transduction in vitro and in vivo
To address whether exogenous IFN-α has a negative impact
on lentiviral transduction, a vector transduction assay was
performed by infecting Huh7 cells with LV-GFP vector
(Fig. 2a) in the absence or presence of 1, 10, or 100 IU/ml
of IFN-α. At day 3, transduction efficiency was assessed by
flow cytometry for GFP-positive cells (Fig. 2b). When
compared with nontreated control group (93±2%, mean±
SD, n=4), 1, 10, or 100 IU/ml concentration of IFN-α had
no significant effect on vector transduction at MOI of 9
(97±0.4%, 97±0.9%, and 93±4%, respectively; P>0.05).
Similar results were observed at medium (3 MOI) and low
(1 MOI) vector concentrations (Fig. 2c). Also, pretreatment
of cells with IFN-α for 24 h did not influence vector
transduction (data not shown).
To further investigate the effects of exogenous IFN-α on
lentiviral transductions in vivo, mice were treated with peg-
IFN-α 6 h before and 72 h after to intravenous adminis-
tration of LV-GFP. As shown in Fig. 2d, there was no
significant effect of peg-IFN-α treatment on vector trans-
duction in mice livers (1.7% to 4.1% transduced hepato-
cytes) compared to untreated transduction group injected
with vector only (2.1% and 4.7% transduced hepatocytes).
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Fig. 2 Effect of exogenous
IFN-α on lentiviral vector
transductions in vitro and in
mice. a LV-GFP vector express-
ing GFP under control of CAG
promoter was used for trans-
duction of Huh7 cells. b Repre-
sentative histogram of GFP
expression determined by flow
cytometry of control cells and
transduced cells 3 days after
culture. c No significant (P>
0.05) differences of transduction
efficiency, compared with non-
treated control group, were ob-
served with 1, 10, or 100 IU/ml
of IFN-α for high (9 MOI),
intermediate (3 MOI), and low
(1 MOI) vector concentrations.
Shown is the mean±SD of four
independent experiments. MOI
multiplicity of infection. d Mice
treated with exogenous IFN-α
6 h before and 3 days after
administration of LV-GFP (sub-
optimal dose, 5×10
6 transduc-
ing units) showed comparable
transduction efficiency in the
liver (1.7% to 4.1% transduced
hepatocytes), compared with the
group injected with vector only
(2.1% and 4.7% transduced
hepatocytes). Percentage of
GFP-positive cells was indicated
in the FACS picture for each
individual mouse
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In the setting of combining RNAi with IFN-α, a critical
concern would be the influence of exogenous IFN-α on
RNAi gene silencing efficiency. To evaluate this issue, a
lentiviral vector expressing shRNA to target report gene
GFP (LV-shGFP; Fig. 3a) was produced, and gene-silencing
efficacy was determined in the absence or presence of IFN-α.
First, a stable GFP expressed cell line (Huh7-GFP) was
created by infecting naive Huh7 cells with LV-GFP and
expanded for several passages. Huh7-GFP cells were treated
with LV-shGFP with or without IFN-α. LV-shGFP signifi-
cantly inhibited GFP mean fluorescence intensity in Huh7-
GFP cells (Fig. 3b) by 74.7±2.6% (mean±SD, n=3, P<
0.01). Treatment of 1, 10, or 100 IU/ml IFN-α did not
significantly interfere with LV-shGFP-mediated GFP knock-
down (79.1±1.9%, 79.5±1.4%, and 74.9±10%, respectively,
P>0.05; Fig. 3c).
To further confirm these findings, LV-shCD81 was used
to target HCVentry receptor CD81. The LV-shCD81 vector
contains a GFP reporter gene to track transduction
efficiencies (Fig. 4a). CD81 knockdown was determined
by flow cytometry based on the GFP-positive population
(Fig. 4b, c). LV-shCD81, compared with LV-GFP control
vector, significantly reduced CD81 expression by 90.8±
8.1% (mean±SD, n=3, P<0.01). Importantly, knockdown
of CD81 in Huh7 cells dramatically reduced infection by
the JFH1-derived infectious HCV particles (Fig. 4d). As
s h o w ni nF i g .4e, LV-shCD81 retained robust gene
silencing efficacy in the IFN-α (1, 10, or 100 IU/ml)
treatment groups (83.9±12.9%, 87.2±9.6%, and 84.3±
11.6%, respectively). Similar results were obtained using
other hepatoma cell line, Huh6 (data not shown). Taken
together, these results indicate that exogenous IFN-α does
not interfere with RNAi-mediated gene silencing.
Simultaneous and sequential combined antiviral activity
of IFN-α and RNAi
The finding that IFN-α did not affect transduction efficacy
and gene silencing prompted the question whether IFN and
RNAihavecombinedantiviral effects onHCVreplication.As
shown in Fig. 1b, LV-shNS5b has potent antiviral activity.
Combination of low-dose IFN-α (<1 IU/ml) with low vector
dose (MOI≤5) resulted in a significant enhanced antiviral
effect (Fig. 5a). For example, combination of 1 MOI vector
with 0.9 IU/ml IFN-α showed 92.1±8.1% (mean±SD, n=6,
P<0.01) inhibition versus 72.2±9.4% with vector alone or
71.5±4.1% with IFN-α alone. Real-time quantitative PCR
confirmed the results in this group of treatments (data not
shown). At high-dose vector (MOI≥10), inhibition of HCV
replication was nearly complete, and therefore, no significant
combinational effect with IFN could be observed.
In order to more clearly show the combined antiviral
effect of IFN-α and RNAi, a less potent vector containing
both GFP and shRNA targeting HCV IRES was used
(Fig. 5b). Huh7-ET treated with increasing dose of LV-
shIRES vector resulted in higher levels of transduction
efficiency and inhibition of HCV replication, monitored by
GFP-positive population and luciferase activity, respectively.
There was a clear threshold for the level of HCV silencing
observed at vector dose of MOI 20 and higher (Fig. 5b).
Similar to the results with LV-shNS5B vector, a combination
of low-dose IFN-α with LV-shIRES resulted in enhanced
inhibition of HCV replication at each combined condition.
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Fig. 3 IFN-α does not interfere with RNAi-mediated knockdown of
GFP. a LV-shGFP vector containing a shGFP cassette driven by U6
promoter were used. b Control (Huh7) and stable GFP expressing cell
line (Huh7-GFP) were treated with LV-shGFP. GFP expression was
measured by flow cytometry 3 days post- transductions, clearly
showing inhibition of GFP expression by LV-shGFP in Huh7-GFP
cells. c The relative GFP expression based on the mean fluorescence
intensity. LV-shGFP significantly inhibited GFP expression by 74.7±
2.6% (P<0.01), and treatment of 1, 10, or 100 IU/ml of IFN-α did not
interfere with the knockdown by LV-shGFP. Shown is the mean±SD
of three independent experiments (*P<0.01)
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0.9 IU/ml IFN-α enhanced inhibition of HCV replication to
86.8%±3.4 compared to vector alone (56.4%, n=6, P<
0.001) or IFN-α alone (72.5%, P<0.05; Fig. 5c). Real-time
quantitative PCR confirmed the results in this group of
treatments (data not shown).
To further investigate this combined antiviral activity,
Huh7-ET cells were sequentially treated with IFN-α and
RNAi. Cells were treated with suboptimal dose of IFN-α
(0.5 IU/ml) for 24 h followed by a secondary treatment with
either LV-shNS5b or again with IFN-α.A ss h o w ni nF i g .6a,
cells were more sensitive to subsequent treatment with RNAi
than to re-treatment with IFN-α. Maximal inhibition of HCV
replication with IFN-α was 81.3%±1.3 (n=7) versus 98.2%±
0.2 inhibition (n=6) with LV-shNS5b (P<0.001). This
indicates that HCV treated with IFN-α remains sensitive to
RNAi, more so than to additional IFN-α. Conversely,
treatment of LV-shIRES led to partial inhibition of viral
replication and was more sensitive to secondary treatment
with IFN-α than re-treatment of the same vector (Fig. 6b). At
48 h after the initial treatment of LV-shIRES, additional
treatment of IFN-α (0.9 IU/ml) resulted in 96.0%±0.6
inhibition of viral replication versus 75.1%±3.7 inhibition
after re-treatment with LV-shIRES (n=6, P<0.001).
Takentogether, these results indicatethat RNAi and IFN-α
actindependentlyonHCVreplicationandthatcombinationof
these agents resulted in an enhanced antiviral effect. Further-
more, IFN-α and RNAi appear complementary, suggesting
that viral resistance to treatment of IFN-α remains sensitive to
treatment with RNAi and, reversely, that viral resistance to
RNAi remains sensitive to inhibition by IFN-α.
Discussion
Peg-IFN-α in combination with ribavirin is currently the
standard therapy for chronic HCV leading to a sustained
viral response in approximately half of patients with the
common genotypes [28]. In order to improve treatment
outcomes and to provide opportunities to treat previous
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Fig. 4 IFN-α does not interfere with RNAi-mediated silencing of
CD81. a LV-shCD81 vector containing a GFP reporter gene and
shRNA targeting CD81 was used to transduce Huh7 cells. LV-GFP
vector without shRNA cassette was used as control. b Three days after
transfection, GFP-positive transduced cells were gated to determine
CD81 expression. c Representative CD81 expression histogram of
GFP-positive cells is shown. Isotype-matched control antibody
staining of LV-shCD81 cells was included as negative control. d
Knockdown of CD81 in Huh7 cells profoundly reduced HCV
infection. Three days after LV-shCD81 transduction, Huh7 cells were
exposed to JFH1-derived infectious HCV particles for 6 h. Three days
after infection, the LV-shCD81 treated cells showed a clear reduction in
intracellular viral RNA levels as determined by quantitative RT-PCR. e
Relative CD81 expression was calculated based on mean fluorescence
intensity. LV-shCD81 significantly reduced CD81 expression by 90.8±
8.1% (P<0.01), compared to LV-GFP cells. LV-shCD81 retained robust
gene silencing efficacy at different concentrations of IFN-α.S h o w ni s
the mean±SD of three independent experiments (*P<0.01)
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RNAi represents as a novel antiviral strategy that could be
effective for HCV. To be applicable in therapeutic setting, it
is critical that RNAi induces long-term and stable gene
silencing. Since integrating lentiviral vectors have shown
great advantages in transgenic delivery [29], third-
generation LV are currently the best option for stable
shRNA delivery. We found that LV and RNAi can be
applied in combination with IFN-α without effecting
transduction to hepatocytes or interfering with RNAi-
mediated gene silencing.
The action of RNAi technology is clearly different from
conventionalantiviralcompounds.Particularlywhendelivered
by a HIV derived lentiviral vector, the first concern would be
whether the vector itself could have complicated interaction
with innate immune system, especially IFN response. The
induction of an endogenous IFN response by shRNA express-
ing vectors is dependent on the cell type and the sequence.
Studies have demonstrated that human dendritic cells can
mount an IFN response after exposure to wild-type HIV or
lentiviral vectors [30–32]. To our knowledge, our current
study is the first report on the effect of exogenous IFN-α on
lentiviral transduction and RNAi. A recent study has shown
that lentiviral vector triggers a type I interferon (IFN-α/β)
response that restricts hepatocyte gene transfer and promotes
vector clearance in mice [24]. These mouse experiments
contradict our experiment in NOD/SCID mice where no
negative effect of exogenous peg-IFN-α treatment was
observed on transduction of hepatocytes (Fig. 2d). Also,
previous studies by others [33, 34] and our group [13]
showed no in vitro evidence of endogenous type I interferon
responses after transduction with lentiviral vectors. The fact
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Fig. 5 Enhanced inhibition of HCV replication by simultaneous
treatment with IFN-α and RNAi. a The structure and action of LV-
shNS5b on HCV replication have been shown in Fig. 1b. The
combination of low-dose IFN-α (<1 IU/ml) with low-dose vector
(≤10 MOI) resulted in enhanced antiviral effects. For example,
combination of 1 MOI vector with 0.9 IU/ml IFN-α showed 92.1%±
8.1 inhibition, versus 72.2%±9.4 with vector alone or 71.5±4.1% with
IFN-α alone (mean±SD, P<0.01). Also, with 5 MOI, a significant
combinational effect was observed (P<0.05), but at higher MOIs,
inhibition of HCV replication was nearly complete, and no significant
additive effect of IFN-α was observed. b LV-shIRES vector contain-
ing GFP reporter gene and shRNA targeting HCV IRES was used to
transduce Huh7-ET cells. Increasing dose of LV-shIRES resulted in
higher levels of transduction efficiency and inhibition of HCV
replication, shown by GFP positivity and luciferase activity, respec-
tively. c Combining low-dose IFN-α with LV-shIRES resulted in
enhanced inhibition of HCV replication at each combined condition.
Shown is the mean±SD of six independent experiments (*P<0.05)
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LV transductions makes a combined approach feasible.
In the setting of combining RNAi with IFN-α, the most
critical issue would be the influence of exogenous IFN-α
on gene silencing efficiency. This study has clearly shown
that IFN-α does not have significant negative effects on
RNAi-mediated silence of both GFP report gene and native
host gene CD81. Down regulation of viral-binding co-
receptor CD81 expression was previously shown to reduce
HCV E2 envelope binding [35]. Now, we (Fig. 4d) and
others [36] have shown RNAi-mediated reduction of CD81
also inhibit infection of replication competent HCV virus,
JFH1. Therefore, it is conceivable that lentiviral-mediated
RNAi has the potential not only to inhibit viral replication
but also to prevent infection. Most importantly, a simulta-
neous combination of IFN-α with RNAi directly targeting
viral genome (IRES or NS5b region) significantly enhanced
their individual antiviral effects. Furthermore, IFN-α and
RNAi clearly acted complementary shown by the fact that
cells treated with IFN-α were more sensitive to subsequent
treatment with RNAi than to re-treatment with IFN-α.
Conversely, treatment of LV-shIRES led to partial inhibition
of viral replication and was more sensitive to secondary
treatment with IFN-α than re-treatment of the same vector
(Fig. 6b). These findings could suggest that HCV that
develops resistance to treatment with IFN-α would still be
sensitive to RNAi therapy and, reversely, that potential viral
resistance developed against RNAi would still be suscep-
tible to inhibition by IFN-α.
Owing to the high risk of escape and resistance
development, combination of RNAi with IFN-α may be
necessary to completely cure HCV infection by attacking
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Fig. 6 Subsequential treatment of IFN-α and RNAi reciprocally
enhances inhibition of HCV replication. a Huh7-ET cells were treated
with low dose (0.5 IU/ml) of IFN-α 24 h after which medium was
replaced, and cells were treated a second time for an additional 86 h.
Secondary treatment with IFN-α resulted in a maximum inhibition of
81.3%±1.3 (n=7, P<0.001) from t=42 h onward. However, subse-
quently switching IFN-α to LV-shNS5b resulted in a significantly
greater inhibition of viral replication (98.2%±0.2 inhibition, n=6, P<
0.001). In Huh7-ET cells without secondary treatment, HCV replica-
tion was partially restored to approx. two third of baseline levels at
2 days after switching. b Conversely, Huh7-ET cells primarily treated
with LV-shIRES were more sensitive to a secondary treatment with
IFN-α than re-treatment with the same LV-shIRES vector. Secondary
treatment with 0.9 IU/ml IFN-α resulted in profound inhibition of
viral replication (96%±0.6 inhibition at t=96 h, n=6, P<0.001) as
compared to secondary treatment with vector (75.1%±3.7 inhibition,
n=6). In Huh7-ET, cells without additional treatment HCV replication
was (66.4%±5.4 inhibition, n=6). Overall, these findings indicate that
cells treated with IFN-α are more sensitive to subsequential treatment
with RNAi than re-treatment with IFN-α. Equally, cells treated with
RNAi are more sensitive to subsequential treatment with IFN-α than
re-treatment with RNAi
720 J Mol Med (2009) 87:713–722the virus in two distinct ways. In particular, this approach
possesses unique advantages in preventing and treating
HCV recurrence after liver transplantation. Lentiviral-
mediated RNAi could be used to modify a donor graft
and prevent or slow HCV recurrence after transplantation;
meanwhile, low-dose IFN-α can be used to systemically
treat HCV enhancing the therapeutic effects of both.
Additional combinations with ribavirin are conceivable in
order to further enhance therapeutic effects. Our prelimi-
nary results show that ribavirin has no negative effects on
the action of RNAi (data not shown).
In conclusion, in this study, we found that exogenous
IFN-α had no significant negative influence on lentiviral
transduction. In the presence of IFN-α, RNAi-mediated
gene knockdown was unaffected, and moreover, a combi-
nation of viral genome targeted RNAi with IFN-α achieved
enhanced antiviral effects. Therefore, this novel combina-
tion strategy may offer the potential to eliminate HCV
infection in chronically infected patients.
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